MA45280A - Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation - Google Patents

Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Info

Publication number
MA45280A
MA45280A MA045280A MA45280A MA45280A MA 45280 A MA45280 A MA 45280A MA 045280 A MA045280 A MA 045280A MA 45280 A MA45280 A MA 45280A MA 45280 A MA45280 A MA 45280A
Authority
MA
Morocco
Prior art keywords
antibulin
methods
drug conjugates
based drug
conjugates
Prior art date
Application number
MA045280A
Other languages
English (en)
Other versions
MA45280B1 (fr
Inventor
Earl F Albone
Xin Cheng
Daniel W Custar
Keiji Furuuchi
Jing Li
Utpal Majumder
Toshimitsu Uenaka
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA45280A publication Critical patent/MA45280A/fr
Publication of MA45280B1 publication Critical patent/MA45280B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA45280A 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation MA45280B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302562P 2016-03-02 2016-03-02
PCT/US2017/020529 WO2017151979A1 (fr) 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA45280A true MA45280A (fr) 2019-01-09
MA45280B1 MA45280B1 (fr) 2021-08-31

Family

ID=58347964

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45280A MA45280B1 (fr) 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Country Status (35)

Country Link
US (4) US10548986B2 (fr)
EP (2) EP3824909A1 (fr)
JP (6) JP6599019B2 (fr)
KR (4) KR20220101204A (fr)
CN (4) CN108883198B (fr)
AR (3) AR107787A1 (fr)
AU (3) AU2017225982B2 (fr)
BR (1) BR112018067379A2 (fr)
CA (2) CA3297123A1 (fr)
CL (3) CL2018002456A1 (fr)
CO (1) CO2018008667A2 (fr)
CY (1) CY1124628T1 (fr)
DK (1) DK3423105T3 (fr)
ES (1) ES2880402T3 (fr)
HR (1) HRP20211125T1 (fr)
HU (1) HUE054726T2 (fr)
IL (3) IL292946B2 (fr)
JO (3) JOP20170053B1 (fr)
LT (1) LT3423105T (fr)
MA (1) MA45280B1 (fr)
MD (1) MD3423105T2 (fr)
MX (4) MX2018010562A (fr)
MY (2) MY199595A (fr)
PE (3) PE20181953A1 (fr)
PH (1) PH12018501847A1 (fr)
PL (1) PL3423105T3 (fr)
PT (1) PT3423105T (fr)
RS (1) RS62108B1 (fr)
RU (1) RU2754369C2 (fr)
SG (2) SG11201806515RA (fr)
SI (1) SI3423105T1 (fr)
SM (1) SMT202100416T1 (fr)
TW (3) TWI772288B (fr)
UA (1) UA125024C2 (fr)
WO (1) WO2017151979A1 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (fr) * 2005-04-22 2010-04-07 Morphotek Inc. Anticorps presentant une activite d'effecteur immunitaire et s'internalisant dans des cellues positives de recepteur alpha de folate
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
CA2990785C (fr) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. Anticorps anti-recepteur de transferrine humaine passant au travers de la barriere hematoencephalique
MY199595A (en) * 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
TWI791006B (zh) 2016-12-26 2023-02-01 日商Ｊｃｒ製藥股份有限公司 包含bdnf之融合蛋白質
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
SI3606928T1 (sl) 2017-04-05 2023-02-28 President And Fellows Of Harvard College Makrociklična spojina in njene uporabe
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US12564632B2 (en) 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
CN111566113B (zh) 2017-11-15 2024-01-09 哈佛大学的校长及成员们 大环化合物及其用途
IL278740B2 (en) 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
CN119405833A (zh) * 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
MX2020014083A (es) 2018-07-05 2021-04-12 Hangzhou Dac Biotech Co Ltd Un derivado de dímero de pirrolobenzodiazepina (pbd) reticulado y sus conjugados.
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
BR112021001750A2 (pt) 2018-08-06 2021-04-27 Daiichi Sankyo Company, Limited composição farmacêutica
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
AU2019409132B2 (en) * 2018-12-21 2026-08-06 Novartis Ag Antibodies to PMEL17 and conjugates thereof
CN110568121A (zh) * 2019-07-11 2019-12-13 山东省药学科学院 一种艾日布林及含艾日布林的制剂中有关物质的检测方法
WO2021090062A1 (fr) * 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Conjugués anticorps-médicament d'éribuline dirigés contre la mésothéline et procédés d'utilisation
CA3164797A1 (fr) * 2019-12-23 2021-07-01 Eisai R&D Management Co., Ltd. Procede de production d'un conjugue anticorps-medicament a base d'eribuline
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
WO2021154477A1 (fr) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anticorps anti-récepteur de la transferrine (tfr) et utilisations associées
CN113274507B (zh) * 2020-02-20 2025-02-28 亚飞（上海）生物医药科技有限公司 靶向递送和激活的免疫刺激性偶联复合物的制备和用途
CN113509557A (zh) * 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
EP4161966A1 (fr) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Conjugués anticorps anti-bcma-médicament et procédés d'utilisation
WO2022010797A2 (fr) * 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Nouveaux maytansinoïdes en tant que charges utiles d'adc et leur utilisation pour le traitement du cancer
WO2022031150A1 (fr) * 2020-08-07 2022-02-10 주식회사 피노바이오 Conjugué comprenant un agent anticancéreux à base de désoxycytidine et un lieur contenant un éther de silyle
CN116601173A (zh) * 2020-09-11 2023-08-15 阿雷克森制药公司 抗铜蓝蛋白抗体及其用途
CA3196055A1 (fr) * 2020-09-28 2022-03-31 Navrogen, Inc. Composition et utilisation d'anticorps anti-mesotheline formates autrement, dans le traitement du cancer
WO2022082068A1 (fr) * 2020-10-18 2022-04-21 Ardeagen Corporation Agents de liaison anti-msln, leurs conjugués et leurs procédés d'utilisation
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
KR20230117182A (ko) * 2020-12-04 2023-08-07 다인 세라퓨틱스, 인크. 항체-올리고뉴클레오티드 복합체 및 그의 용도
EP4241789A4 (fr) * 2020-12-08 2025-04-02 Nona Biosciences (Shanghai) Co., Ltd. Conjugué protéine-médicament et procédé de conjugaison spécifique à un site
CN115209922A (zh) * 2021-01-28 2022-10-18 南京桦冠生物技术有限公司 缀合物及其用途
JP2024504454A (ja) * 2021-01-29 2024-01-31 上▲海▼翰森生物医▲薬▼科技有限公司 抗体－薬物コンジュゲート及びその医学的使用
WO2022217022A1 (fr) * 2021-04-10 2022-10-13 Profoundbio Us Co. Agents de liaison à folr1, conjugués de ceux-ci et leurs procédés d'utilisation
EP4349371A4 (fr) * 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. Conjugué de médicament et utilisation associée
MX2024000893A (es) * 2021-07-22 2024-02-06 Shanghai Senhui Medicine Co Ltd Farmaco conjugado de un derivado de eribulina.
EP4385522A1 (fr) * 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Conjugué anticorps-médicament à base d'inhibiteur de microtubules
EP4393514A1 (fr) * 2021-08-24 2024-07-03 Kunshan Xinyunda Biotech Co., Ltd. Conjugué anticorps-médicament conjugué par l'intermédiaire d'un lieur cassable
IL311324A (en) * 2021-09-16 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A drug-antibody conjugate against HER3, a preparation including it and its use
WO2023055376A1 (fr) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Anticorps multispécifiques pour cibler cd47 et icam1 et leurs procédés d'utilisation
TW202317088A (zh) * 2021-10-14 2023-05-01 大陸商江蘇恒瑞醫藥股份有限公司 艾日布林衍生物的製備方法
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN116199740A (zh) * 2021-12-01 2023-06-02 上海生物制品研究所有限责任公司 抗体药物偶联物及其用途
WO2023103854A1 (fr) * 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament présentant une affinité améliorée, son procédé de préparation et son application
WO2023124963A1 (fr) * 2021-12-27 2023-07-06 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament ayant une réaction réversible réduite, procédé de préparation s'y rapportant et application associée
CN118591394A (zh) * 2022-01-28 2024-09-03 启德医药科技（苏州）有限公司 抗体药物偶联物、药物组合物及用途
WO2023143320A1 (fr) * 2022-01-28 2023-08-03 博瑞生物医药（苏州）股份有限公司 Lieur pour la préparation d'un conjugué anticorps-médicament, composé et utilisation
EP4480499A1 (fr) * 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugué d'anticorps-éribuline ou un dérivé de celui-ci, intermédiaire de celui-ci, son procédé de préparation, composition pharmaceutique de celui-ci et son utilisation
AU2023231442B2 (en) 2022-03-11 2026-07-02 Mablink Bioscience Antibody-drug conjugates and their uses
WO2023200814A1 (fr) 2022-04-12 2023-10-19 Eisai R & D Management Co., Ltd. Conjugués anticorps-médicament à base d'éribuline et procédés d'utilisation
EP4509141A4 (fr) * 2022-04-12 2026-08-19 Bio Thera Solutions Ltd Méthode de traitement d'une tumeur solide positive à her2
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
WO2024078612A1 (fr) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Composé de charge utile et de lieur, conjugués et applications associées
CN117917248A (zh) 2022-10-20 2024-04-23 英诺湖医药(杭州)有限公司 酶裂解连接子及包含其的配体-艾瑞布林偶联物
EP4619038A2 (fr) * 2022-11-14 2025-09-24 Cornell University Polypeptides à fonctionnalité anionique, ainsi que procédés de fabrication et utilisations y relatifs
AU2024209545A1 (en) 2023-01-17 2025-08-07 Systimmune, Inc. Conjugate of eribulin drug
WO2024153224A1 (fr) * 2023-01-19 2024-07-25 江苏恒瑞医药股份有限公司 Composition pharmaceutique contenant un conjugué de médicament dérivé de l'éribuline
WO2024173281A1 (fr) * 2023-02-13 2024-08-22 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Conjugué anticorps-médicament pour le traitement du cancer
WO2024235135A1 (fr) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 Composé macrocyclique et son procédé de préparation et son utilisation
WO2024235131A1 (fr) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 Conjugué de médicament macrocyclique, son procédé de préparation et son utilisation
EP4710946A1 (fr) * 2023-05-12 2026-03-18 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugué anticorps-médicament multiprojectile multiples, son procédé de préparation et son utilisation
JP2024165695A (ja) 2023-05-18 2024-11-28 セイコーエプソン株式会社 印刷方法、印刷ヘッドユニットおよびロボットシステム
EP4725969A1 (fr) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Conjugué anticorps-médicament bispécifique complémentaire anti-her2, son procédé de préparation et son utilisation
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
WO2025027529A1 (fr) 2023-07-31 2025-02-06 Advesya Conjugués médicament-anticorps anti-il-1rap et leurs procédés d'utilisation
IL327670A (en) 2023-10-11 2026-06-01 Antikor Biopharma Ltd Antibodies, conjugates, and uses thereof
TW202530697A (zh) 2023-10-13 2025-08-01 日商衛材R&D企管股份有限公司 用於基於艾日布林之抗體－藥物結合物之生物標記及使用方法
CN122349614A (zh) 2023-10-13 2026-07-07 卫材R&D管理有限公司 抗体-药物缀合物代谢物
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025106586A1 (fr) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Composés cétoniques macrocycliques et leurs applications
AU2024397535A1 (en) * 2023-12-13 2026-07-02 Systimmune, Inc. Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025162492A1 (fr) * 2024-01-29 2025-08-07 甘李药业股份有限公司 Lieur, conjugué ligand-médicament et utilisation médicale associée
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
WO2025199464A1 (fr) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Conjugués anticorps-médicament anti-trop2 et procédés d'utilisation
WO2025228172A1 (fr) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 Dérivé d'éribuline, conjugué anticorps-médicament de celui-ci et utilisation médicale associée
WO2026037417A1 (fr) * 2024-08-15 2026-02-19 上海睿智医药技术有限公司 Nouvelle molécule active liée à l'éribuline, composé de molécule de toxine de lieur-médicament la contenant, et son utilisation dans un conjugué d'anticorps
WO2026120507A1 (fr) 2024-12-04 2026-06-11 Daiichi Sankyo Company, Limited Conjugué anticorps-médicament destiné à être utilisé dans le traitement du cancer résistant aux médicaments

Family Cites Families (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0871490B1 (fr) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Segments de liaison hydrazone ramifies
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
US6019963A (en) 1998-11-20 2000-02-01 D.S.C. Products, Inc. Deodorizing composition containing tea tree and eucalyptus oils
US7109019B2 (en) 1999-01-06 2006-09-19 The Regents Of The University Of California Gene cluster for production of the enediyne antitumor antibiotic C-1027
IL158532A0 (en) 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
WO2003072754A2 (fr) 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugues de ligand, adaptateur et agent cytotoxique, compositions associees et procedes d'utilisation relatifs
ES2369542T3 (es) * 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
JP2004119755A (ja) 2002-09-27 2004-04-15 Alps Electric Co Ltd 磁気検出素子及びその製造方法
US20040071540A1 (en) 2002-10-15 2004-04-15 Lucas Philip J. Disposable/recyclable pallet system and method
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
CA2522345A1 (fr) 2003-04-09 2004-11-18 Neose Technologies, Inc. Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
AU2004273910A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US6997024B2 (en) 2003-10-01 2006-02-14 Truth Hardware Corporation Pull door lock
US20050148535A1 (en) 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
CA2556027C (fr) 2004-02-12 2015-11-24 Morphotek, Inc. Anticorps monoclonaux qui bloquent specifiquement l'activite biologique d'un antigene tumoral
US7117807B2 (en) 2004-02-17 2006-10-10 University Of Florida Research Foundation, Inc. Dynamically modifiable polymer coatings and devices
US20080253960A1 (en) 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
CA2569003A1 (fr) 2004-05-07 2005-12-08 Massachusetts Institute Of Technology Procede et compositions pour traitement du cancer relatif a la reconnaissance du domaine brca1 brct de bach1 phosphoryle
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 ｂ 유사체의 제조를 위한 중간체
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008522624A (ja) 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
JP2008522623A (ja) 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
WO2007008848A2 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications carboxy phenylalanine a la terminaison c
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
GB0515025D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
RU2470668C2 (ru) 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
WO2007031734A1 (fr) 2005-09-14 2007-03-22 Ucb Pharma S.A. Polymères à structure en peigne
US8293726B2 (en) 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
WO2007128884A1 (fr) 2006-05-09 2007-11-15 Oy Jurilab Ltd Gènes et marqueurs atypiques dans le diabète de type 2 et l'obésité
US20140037539A1 (en) 2012-07-27 2014-02-06 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US20150030534A1 (en) 2013-07-26 2015-01-29 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP1977765A1 (fr) 2007-04-03 2008-10-08 Diatos Promédicaments de peptide
EP2578576B9 (fr) 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermédiaires pour la synthèse d'analogues d'halichondrine b
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
WO2009057304A1 (fr) 2007-10-30 2009-05-07 Fujitsu Limited Dispositif de terminal mobile
WO2009117531A1 (fr) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Conjugués auristatine-lieur de médicament
EP2279267A4 (fr) 2008-03-27 2012-01-18 Vascular Biosciences Inc Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (fr) 2008-04-29 2012-04-25 Abbott Lab Immunoglobulines à double domaine variable et utilisations
UA108598C2 (xx) * 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
GEP20135804B (en) 2008-09-12 2013-04-10 Santen Pharmaceutical Co Ltd Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent
SG171812A1 (en) 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US20140339088A1 (en) 2009-03-09 2014-11-20 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
WO2010127284A2 (fr) 2009-05-01 2010-11-04 Abbott Laboratories Immunoglobulines à deux domaines variables et ses utilisations
US8686520B2 (en) * 2009-05-29 2014-04-01 International Business Machines Corporation Spin-torque magnetoresistive structures
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20120107069A (ko) * 2009-08-15 2012-09-28 제넨테크, 인크. 이전에 치료된 유방암의 치료를 위한 항혈관신생 요법
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
EP2549863A4 (fr) 2010-03-24 2014-01-01 Univ Ohio Compositions et procédés pour l'inhibition du transport du glucose
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Ｉｌ－１結合蛋白
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9089570B2 (en) 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
EP2613810B9 (fr) 2010-09-07 2016-02-17 Johannes Kepler Universität Linz Poly(organo)phosphazènes biodégradables, hydrosolubles et répondant au ph
WO2012065057A2 (fr) 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation
WO2012065019A2 (fr) 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs pyridopyrimidinone de p13k alpha
CA2814962A1 (fr) 2010-12-02 2012-06-07 Immunomedics, Inc. Chimie click exempte de cuivre in vivo pour l'administration d'agents therapeutiques et/ou diagnostiques
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012119077A1 (fr) 2011-03-02 2012-09-07 Morphotek Inc. Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
WO2012118978A1 (fr) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Procédés pour traiter des cancers positifs aux oncovirus
CN103502218B (zh) 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
JP5971769B2 (ja) 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル アントラサイクリン療法を用いて乳癌を処置する方法
EP2686441B1 (fr) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Procédé et utilisation pour prédire la réponse à l'éribuline
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
EP2670866A4 (fr) 2011-04-05 2015-09-02 Translational Genomics Res Inst Biomarqueurs et leurs procédés d'utilisation
WO2012145098A1 (fr) 2011-04-21 2012-10-26 Saint Louis University Utilisation d'agonistes du récepteur à l'adénosine a3 pour le traitement de la douleur neuropathique
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
KR20200128601A (ko) 2011-05-27 2020-11-13 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
WO2012170640A1 (fr) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Procédés et compositions pour traitement par une combinaison trail-médicament
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2717916B1 (fr) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Conjugués protéine-polymère-médicament
CA2842492A1 (fr) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. Fragments de p97 avec activite de transfert
CA2857385A1 (fr) 2011-11-30 2013-06-06 Alphora Research Inc. Procede de preparation de (3r)-2,4-di-groupe partant-3-methylbut-1-ene
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
EP3539982B1 (fr) 2011-12-23 2025-02-19 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
CA2858806A1 (fr) 2011-12-23 2013-06-27 Innate Pharma Conjugaison enzymatique de polypeptides
IN2014MN01521A (fr) 2011-12-29 2015-05-01 Alphora Res Inc
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2013130093A1 (fr) * 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2013138371A1 (fr) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Procédés de traitement du cancer du pancréas à l'aide de thérapies combinées comprenant un anticorps anti-erbb3
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
AU2013240191B2 (en) 2012-03-29 2018-02-22 Altor Bioscience Corporation Methods for treating neoplasia
CN104334562A (zh) 2012-03-30 2015-02-04 阿方拉研究股份有限公司 用于制备软海绵素b的大环c1-酮类似物的合成方法及其中有用的中间体
CN104684579A (zh) 2012-04-02 2015-06-03 梅里麦克制药股份有限公司 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
WO2013172955A1 (fr) 2012-05-15 2013-11-21 Diatech Oncology Procédé d'isolement/purification de cellules tumorales et leurs procédés d'utilisation
EP3536700A1 (fr) 2012-06-07 2019-09-11 Ambrx, Inc. Conjugués anticorps-médicament d'antigène membranaire spécifique à la prostate
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
CN111499684B (zh) 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
JP2015530072A (ja) 2012-06-29 2015-10-15 ナノストリング テクノロジーズ，インコーポレイティド ゲムシタビン療法による乳癌の治療方法
US9220695B2 (en) 2012-06-29 2015-12-29 The Research Foundation For The State University Of New York Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
US9872919B2 (en) 2012-09-19 2018-01-23 The Research Foundation For The State University Of New York Prodrugs for selective anticancer therapy
AU2013326463B2 (en) 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
WO2014058317A1 (fr) 2012-10-10 2014-04-17 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Procédés et moyens de prédiction de résistance à un traitement anti-cancer
CN103775148A (zh) 2012-10-22 2014-05-07 张玉良 自冷式热力做功方法
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
MX340090B (es) 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
HK1220640A1 (zh) 2012-12-03 2017-05-12 Calithera Biosciences, Inc. 用谷氨醯胺酶的杂环抑制剂治疗癌症
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
WO2014093394A1 (fr) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Conjugués protéine-polymère-médicament
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
US20150314007A1 (en) 2012-12-21 2015-11-05 Glykos Finland Oy Linker-payload molecule conjugates
US20150182634A1 (en) 2012-12-28 2015-07-02 Cody P. Coyne Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
US9695153B2 (en) 2013-01-19 2017-07-04 New York University Oligooxopiperazines for p53 reactivation
WO2014113792A1 (fr) 2013-01-19 2014-07-24 New York University Peptides et peptidomimétiques de substitution à liaison hydrogène pour la réactivation du p53
WO2014121235A2 (fr) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation de compositions de type complexe médicament-cyclodextrine en compositions constituées de mélanges de médicament encapsulé dans des vésicules lipidiques et de complexes cyclodextrine-médicament
KR102310786B1 (ko) 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
WO2014124322A1 (fr) 2013-02-08 2014-08-14 University Of Louisville Research Foundation, Inc. Nanoparticules utilisables en vue de l'administration de médicaments
US9333211B2 (en) 2013-02-22 2016-05-10 University Of Houston System Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
ES2687439T3 (es) * 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
WO2015073072A1 (fr) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
WO2014160360A1 (fr) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Composés de tubulysine et leurs conjugués
US20160038456A1 (en) 2013-03-14 2016-02-11 University Of Florida Research Foundation, Incorporated Regulation of cancer using natural compounds and/or diet
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
WO2014168721A2 (fr) 2013-04-12 2014-10-16 Tufts Medical Center Procédés et systèmes pour mettre au point et/ou caractériser des agents ligands lipidés solubles
EP2988786A4 (fr) 2013-04-22 2016-12-21 Avelas Biosciences Inc Compositions et procédés d'utilisation pour l'administration sélective de médicaments
GB2513405A (en) 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
DK2991683T3 (da) 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
US9650397B2 (en) 2013-05-15 2017-05-16 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
WO2014202773A1 (fr) 2013-06-20 2014-12-24 Innate Pharma Conjugaison enzymatique de polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
US20160299147A1 (en) 2013-06-26 2016-10-13 Afg Technologies S.À.R.L. Screening, diagnosis, prognostication and treatment of ovarian cancer
WO2015000070A1 (fr) 2013-07-03 2015-01-08 Alphora Research Inc. Procédé de synthèse pour la préparation d'analogues c1-céto macrocycliques de l'halichondrine b et intermédiaires utiles dans la synthèse, notamment des intermédiaires contenant des groupes -so2-(p-tolyle)
WO2015017729A1 (fr) 2013-07-31 2015-02-05 Virginia Tech Intellectual Properties, Inc. Procédés de diélectrophorèse pour déterminer une propriété d'une pluralité de cellules cancéreuses
WO2015017034A1 (fr) 2013-08-02 2015-02-05 Gourdie Robert G Procédés de traitement d'un cancer par rupture ciblée de l'interaction alpha connexine 43-zonula occludens-1 (zo-1)
CA2922529A1 (fr) 2013-08-28 2015-03-05 Stemcentrx, Inc. Nouveaux modulateurs sez6 et procedes d'utilisation
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
AU2014317843A1 (en) 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
WO2015038426A1 (fr) 2013-09-13 2015-03-19 Asana Biosciences, Llc Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
US20150093331A1 (en) 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
US9878049B2 (en) 2013-10-09 2018-01-30 The University Of Akron High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy
EP3054987B1 (fr) 2013-10-11 2019-10-09 The United States of America, represented by the Secretary, Department of Health and Human Services Anticorps tem8 et leur utilisation
WO2015054659A1 (fr) 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Conjugués de médicament-protéine-polymère
CA2927022C (fr) 2013-10-11 2018-08-21 Asana Biosciences, Llc Conjugues medicament-polymere-proteine
US9617521B2 (en) 2013-10-21 2017-04-11 Hemoshear, Llc In vitro model for a tumor microenvironment
CA2929084C (fr) 2013-11-04 2022-01-11 Eisai R&D Management Co., Ltd. Reactions et intermediaires de macrocyclisation et autres fragments utiles dans la synthese d'analogues d'halichondrin b
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
AU2013404949B2 (en) 2013-11-07 2018-10-18 Deciphera Pharmaceuticals, Llc Methods for inhibiting TIE2 kinase useful in the treatment of cancer
SMT201900291T1 (it) 2013-11-15 2019-07-11 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
BR112016012237B1 (pt) 2013-12-06 2023-02-07 Eisai R&D Management Co., Ltd Métodos úteis na síntese de análogos de halicondrina b
WO2015095784A1 (fr) 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Formulation de nanoparticules solides d'inhibiteurs des microtubules à mûrissement d'ostwald réduit pour une administration par voie orale
EP3092027A4 (fr) 2014-01-10 2017-09-06 Atossa Genetics Inc. Procédés et compositions transpapillaires pour le dignostic et le traitement de maladies du sein
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
EP3092256B1 (fr) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Composés et compositions pour l'immunothérapie
CN104784699B (zh) 2014-01-20 2019-05-03 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
AU2015211674A1 (en) * 2014-02-03 2016-08-04 Nanocarrier Co., Ltd. Anti-tissue factor monoclonal antibody
EP3730154B1 (fr) 2014-02-03 2021-06-30 Eidgenössiche Technische Hochschule Zürich Conjugués de médicaments à petites molécules
EP2913064A1 (fr) 2014-02-26 2015-09-02 celares GmbH Conjugués de lieurs de médicaments ramifiés pour le couplage à des molécules biologiques de ciblage
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
MA39740A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes
US9260478B2 (en) * 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
JP2017515800A (ja) 2014-04-08 2017-06-15 ザ・メソジスト・ホスピタル ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用
US20170035894A1 (en) 2014-04-14 2017-02-09 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
WO2015161247A1 (fr) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Anticorps anti-c16orf54 humanisés et leurs méthodes d'utilisation
MX378281B (es) * 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
US9808528B2 (en) * 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2016008112A1 (fr) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Lieurs et application à des conjugués anticorps-médicament (acd) associée
EP3069734A1 (fr) * 2015-03-17 2016-09-21 Exiris S.r.l. Conjugués anticorps-médicament à base de cryptophycine avec de nouveaux lieurs auto-immolateurs
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CN116726190A (zh) 2015-06-20 2023-09-12 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
MY199595A (en) * 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use

Also Published As

Publication number Publication date
CL2021000048A1 (es) 2021-05-28
KR102445255B1 (ko) 2022-09-22
TWI772288B (zh) 2022-08-01
MY199595A (en) 2023-11-08
MX2023003806A (es) 2023-04-12
CN114191428B (zh) 2024-09-24
MX2023003808A (es) 2023-04-12
CA3013791C (fr) 2026-07-21
AR121302A2 (es) 2022-05-04
US10548986B2 (en) 2020-02-04
NZ785232A (en) 2025-05-30
NZ744808A (en) 2024-04-26
AU2026201384A1 (en) 2026-03-12
JP2019516664A (ja) 2019-06-20
RU2021125492A (ru) 2022-04-05
CN108883198A (zh) 2018-11-23
RS62108B1 (sr) 2021-08-31
JOP20210073A1 (ar) 2023-01-30
EP3423105A1 (fr) 2019-01-09
MD3423105T2 (ro) 2021-10-31
RU2018134331A3 (fr) 2020-08-14
PH12018501847A1 (en) 2019-05-15
PE20231049A1 (es) 2023-07-11
JP6870051B2 (ja) 2021-05-12
CN114191428A (zh) 2022-03-18
PE20181953A1 (es) 2018-12-17
MY189113A (en) 2022-01-26
AR107787A1 (es) 2018-06-06
US20170252458A1 (en) 2017-09-07
US20180193478A1 (en) 2018-07-12
HRP20211125T1 (hr) 2021-10-15
CY1124628T1 (el) 2022-07-22
IL261428B1 (en) 2025-06-01
DK3423105T3 (da) 2021-07-26
WO2017151979A1 (fr) 2017-09-08
PT3423105T (pt) 2021-07-19
EP3824909A1 (fr) 2021-05-26
CL2018002456A1 (es) 2018-12-21
TWI871094B (zh) 2025-01-21
CA3297123A1 (en) 2026-03-02
CN114272389A (zh) 2022-04-05
KR20180115330A (ko) 2018-10-22
US20230398228A1 (en) 2023-12-14
IL261428A (en) 2018-10-31
CN108883198B (zh) 2022-08-09
RU2018134331A (ru) 2020-04-02
CO2018008667A2 (es) 2018-08-31
JP2020128413A (ja) 2020-08-27
SG10202007520WA (en) 2020-09-29
SI3423105T1 (sl) 2021-12-31
IL261428B2 (en) 2025-10-01
IL320940A (en) 2025-07-01
JP7556086B2 (ja) 2024-09-25
AU2023285804A1 (en) 2024-01-18
KR20240007722A (ko) 2024-01-16
IL292946B2 (en) 2024-11-01
HUE054726T2 (hu) 2021-09-28
JOP20210074A1 (ar) 2023-01-30
ES2880402T3 (es) 2021-11-24
MX2018010562A (es) 2019-02-20
MX2023003809A (es) 2023-04-12
JOP20170053B1 (ar) 2021-08-17
AR121301A2 (es) 2022-05-04
JP2024174991A (ja) 2024-12-17
IL292946B1 (en) 2024-07-01
TW202241524A (zh) 2022-11-01
US20200297860A1 (en) 2020-09-24
CL2021000049A1 (es) 2021-05-28
RU2754369C2 (ru) 2021-09-01
UA125024C2 (uk) 2021-12-29
SMT202100416T1 (it) 2021-09-14
TW201800110A (zh) 2018-01-01
LT3423105T (lt) 2021-09-10
JP7254861B2 (ja) 2023-04-10
PL3423105T3 (pl) 2021-10-25
US10322192B2 (en) 2019-06-18
TWI825834B (zh) 2023-12-11
AU2026201384B2 (en) 2026-05-21
JP2020019787A (ja) 2020-02-06
AU2023285804B2 (en) 2025-12-18
JP6599019B2 (ja) 2019-10-30
CA3013791A1 (fr) 2017-09-08
AU2017225982A1 (en) 2018-08-16
IL292946A (en) 2022-07-01
MA45280B1 (fr) 2021-08-31
JP2021185176A (ja) 2021-12-09
SG11201806515RA (en) 2018-09-27
KR20220101204A (ko) 2022-07-19
JP2023082096A (ja) 2023-06-13
CN114272389B (zh) 2023-04-18
KR20220101203A (ko) 2022-07-19
BR112018067379A2 (pt) 2019-01-15
CN114191563A (zh) 2022-03-18
EP3423105B1 (fr) 2021-05-05
KR102456433B1 (ko) 2022-10-19
PE20231050A1 (es) 2023-07-11
TW202408592A (zh) 2024-03-01
KR102702620B1 (ko) 2024-09-05
AU2017225982B2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
MA48709A (fr) Conjugués de médicament à base de silicium et leurs procédés d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3493676A4 (fr) Compositions antimicrobiennes à base de polymère et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3645063A4 (fr) Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3463440A4 (fr) Compositions de vaccins à base de néo-épitopes et leurs méthodes d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3400097A4 (fr) Mélangeurs à bifurcation et leurs procédés d'utilisation et de fabrication
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3442584A4 (fr) Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation